[go: up one dir, main page]

JP6585193B2 - ゲフィチニブ含有錠剤 - Google Patents

ゲフィチニブ含有錠剤 Download PDF

Info

Publication number
JP6585193B2
JP6585193B2 JP2017559179A JP2017559179A JP6585193B2 JP 6585193 B2 JP6585193 B2 JP 6585193B2 JP 2017559179 A JP2017559179 A JP 2017559179A JP 2017559179 A JP2017559179 A JP 2017559179A JP 6585193 B2 JP6585193 B2 JP 6585193B2
Authority
JP
Japan
Prior art keywords
gefitinib
tablet
weight
polyethylene glycol
lauryl sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017559179A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2017115746A1 (ja
Inventor
倫徳 及川
倫徳 及川
雄樹 西川
雄樹 西川
山本　浩之
浩之 山本
山下　浩平
浩平 山下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sawai Pharmaceutical Co Ltd
Original Assignee
Sawai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sawai Pharmaceutical Co Ltd filed Critical Sawai Pharmaceutical Co Ltd
Publication of JPWO2017115746A1 publication Critical patent/JPWO2017115746A1/ja
Application granted granted Critical
Publication of JP6585193B2 publication Critical patent/JP6585193B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017559179A 2015-12-28 2016-12-26 ゲフィチニブ含有錠剤 Active JP6585193B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015257257 2015-12-28
JP2015257257 2015-12-28
PCT/JP2016/088668 WO2017115746A1 (fr) 2015-12-28 2016-12-26 Comprimé contenant du géfinitib

Publications (2)

Publication Number Publication Date
JPWO2017115746A1 JPWO2017115746A1 (ja) 2018-10-18
JP6585193B2 true JP6585193B2 (ja) 2019-10-02

Family

ID=59224823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017559179A Active JP6585193B2 (ja) 2015-12-28 2016-12-26 ゲフィチニブ含有錠剤

Country Status (2)

Country Link
JP (1) JP6585193B2 (fr)
WO (1) WO2017115746A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6719299B2 (ja) * 2016-07-01 2020-07-08 日本化薬株式会社 ゲフィチニブを有効成分とする医薬組成物
JP6958856B2 (ja) * 2017-08-09 2021-11-02 日本臓器製薬株式会社 錠剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
JP5959000B2 (ja) * 2012-07-11 2016-08-02 大原薬品工業株式会社 結晶系の安定な固形製剤の製造方法
JP6336246B2 (ja) * 2013-03-13 2018-06-06 大同化成工業株式会社 ナノ粒子化製剤及びその製造方法
WO2015097090A1 (fr) * 2013-12-23 2015-07-02 Laboratorios Del Dr. Esteve, S.A. Composition pharmaceutique orale
CN103845335B (zh) * 2014-03-24 2016-07-13 江苏奥赛康药业股份有限公司 吉非替尼药物组合物及含有这一吉非替尼药物组合物的片剂
WO2016096999A1 (fr) * 2014-12-19 2016-06-23 Synthon B.V. Composition pharmaceutique contenant du géfitinib

Also Published As

Publication number Publication date
JPWO2017115746A1 (ja) 2018-10-18
WO2017115746A1 (fr) 2017-07-06

Similar Documents

Publication Publication Date Title
JP5775464B2 (ja) 非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物
US20250144112A1 (en) Suspension for oral administration comprising amorphous tolvaptan
TWI702953B (zh) 包含ａｚｄ９２９１之醫藥組合物及錠劑以及其用途
JP7046978B2 (ja) 水溶解度及びバイオアベイラビリティが改善された組成物
JP6183979B2 (ja) アリピプラゾール無水物を含有する固形製剤の製造方法
JP6585193B2 (ja) ゲフィチニブ含有錠剤
EP3437645A1 (fr) Comprimé enrobé d'un film et présentant une stabilité chimique élevée de son principe actif
AU2023201826A1 (en) Solid formulation having excellent stability
ES2622568T3 (es) Comprimido que contiene 5-hidroxi-1H-imidazol-4-carboxamida
JP6905781B1 (ja) 不快な味がマスクされた顆粒剤及びその製造方法
US20250221975A1 (en) Pharmaceutical composition and preparation method therefor
JP2025123520A (ja) ニロチニブ錠剤
CN114767641A (zh) 一种司替戊醇固体制剂及其制备方法
CN111278432A (zh) 来那度胺速释制剂
WO2019230937A1 (fr) Forme galénique solide pour la voie orale possédant d'excellentes propriétés de dissolution
TWI501950B (zh) 含喹啉衍生物的藥學組成物
CN114364386B (zh) 一种抗肿瘤药物组合物以及提高化合物的溶解度的方法
JP5563371B2 (ja) クエチアピンフマル酸塩含有経口用錠剤
JPWO2017188362A1 (ja) トスフロキサシントシル酸塩、崩壊剤および酸性アミノ酸を含む錠剤
CN115025056A (zh) 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂
BR112021004047A2 (pt) nova composição farmacêutica de lapatinib e processo para preparar uma nova composição farmacêutica de lapatinib
WO2013137441A1 (fr) Composition pharmaceutique à usage oral
CN105796513A (zh) 一种羟苯磺酸钙药物组合物
HK1216620B (en) Suspension for oral administration comprising amorphous tolvaptan

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190516

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190516

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190904

R150 Certificate of patent or registration of utility model

Ref document number: 6585193

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250